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Background 
General  
Although lung cancer is the fourth most common cancer, it is the leading cause of 
cancer related deaths in Norway 1, as well as throughout the western world 2. In 
Norway, the annual incidence of lung cancer was 2250 in 2003, of which 1387 were 
males and 863 females 1. A 60% incidence increase is registered in females during the 
last decade, while it is stable in males. The long-term survival is low with only 10% 
surviving 5 years following diagnosis. According to the National Cancer Registry 1, 
there has been only incremental increase in long-term survival during the last decades, 
which is in accordance with international reports 3.  
Cigarette smoking is by far the most important etiologic factor for lung cancer, 
responsible for about 90% of the cases 4. In 2002, the fraction of daily smokers among 
Norwegian adults fell below 30% 5. However, the percentage of female smokers in 
Norway is still among the highest in Europe 5.  
 In order to improve survival, symptom palliation, as well as overall quality-of-
life, high-quality randomised constructed trials are necessary to perform, evaluate the 
treatment, and hopefully implement beneficial results into daily clinical practice. 
 
Histopatohology 
The World Health Organisation (WHO) classification on histological typing of lung 
tumours was first published in 1967, with a revised edition in 1981. Since then a 
considerably progress has been made in the understanding of the biology of lung 
cancer, and the concept of neuroendocrine lung carcinoma has been accepted. Table 1 
lists the different types of primary malignant epithelial lung tumours 6.   
 These carcinomas arise from the bronchial epithelium or bronchioalveolar 
surface epithelium and constitute up to 95% of all malignant lung tumours. The major 
histological types are squamous cell carcinoma, small cell lung carcinoma (SCLC), 
adenocarcinoma and large cell lung carcinoma. The three subtypes apart from SCLC 
are grouped as non-small cell lung cancer (NSCLC), since the biology and the natural 
course of the disease is different from SCLC. Most often the histopathologic image is 
typical with a distinct classification in these four subtypes. Some tumours represent 
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Table 1. WHO Histological classification of lung tumours 
Tumour type Frequency 
I. Squamous cell carcinoma (epidermoid carcinoma) 30-50% 
II. Small cell carcinoma 17-20% 
  Variants: 
• Combined small cell carcinoma 
 
III Adenocarcinoma 25-50% 
  Variants: 
• Acinar 
• Papillary 
• Bronchioalveolar 
• Solid adenocarcinoma with mucin 
 
IV Large cell carcinoma 5-15% 
  Variants: 
• Large cell neuroendocrine carcinoma (LCNEC) 
• Large cell basaloide carcinoma 
• Large cell clear cell carcinoma 
 
V Adenosquamous carcinoma 1-2% 
VI Carcinoid tumours 0.5% 
  Variants: 
• Typical carcinoid 
• Atypical carcinoid 
 
VII Others 0.2-0.5% 
 
variants with heterogenic differentiation into several directions. The determined 
histologic subclassification done by the pathologist should be compatible with the 
tumour’s dominant microscopic image. The heterogeneity is often prominent in 
tumours with both SCLC and NSCLC features. The variant combined small cell 
carcinoma is typical where at least 10% of the tumour consists of NSCLC 
components, but appears otherwise as a pure SCLC. However, the major clinical 
question to be answered is whether a lung tumour is a SCLC or a NSCLC, since this 
will have fundamental implications for choice of therapy.  
Pulmonary neuroendocrine tumours are a subgroup of lung neoplasms with 
microscopic and biologic neuroendocrine differentiation. These tumours are separated 
into low-grade tumours (indolent typical carcinoid), medium-grade tumours (atypical 
carcinoid), and high-grade tumours [large-cell neuroendocrine carcinoma (LCNEC) 
and SCLC]. LCNEC tumours were recognised as a separate entity in the late 1980s 
and show an increasing incidence 7. With more widespread use of 
immunohistochemistry, NSCLC tumours are more frequently identified with 
neuroendocrine differentiation. Carcinoid tumours have a much better prognosis than 
high-grade neuroendocrine lung tumours. However, LCNEC and NSCLC with some 
neuroendocrine features have not been found to have specific clinical characteristics 
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requiring a different treatment strategy. Thus, these tumours are treated as ordinary 
NSCLC tumours 8. 
 
Diagnosis, staging and prognosis 
At the suspicion of a malignant lung tumour, the diagnostic procedure should end up 
in a conclusive histology and clinical disease stage of each patient. A chest X-ray 
followed by thoracic CT and bronchoscopy is mandatory. Otherwise, a minimum of 
diagnostic procedures should be performed routinely providing a precise TNM 
classification for NSCLC and a distinction between limited and extensive disease in 
cases of SCLC 9. If metastatic disease is apparent at presentation, investigation should 
be minimised to define the histology and to verify advanced metastatic disease.  
Patients with NSCLC and localised disease are candidates for surgery 10. A 
mediastinoscopi should be carried out if the CT examination reveals enlarged 
mediastinal nodules (> 1 cm) 11. If the tumour is found to be technically operable, a 
precise examination of the cardiovascular and lung function should be performed 12.   
Patients with SCLC histology should primarily be categorised as with limited 
(LD-SCLC) or extensive disease (ED-SCLC) 13. Cases where tumour and local spread 
can be included within a single radiation port, i.e. tumour within the ipsilateral 
hemithorax, should be grouped as LD-SCLC. All others, included pleural fluid with 
positive cytology and/or verified metastatic disease, is defined as ED-SCLC.   
Due to a relatively poor correlation between clinically detected (CT) enlarged 
lymph nodes and verified pathological lymph nodes in the resected specimen, there is 
a significant difference between the clinical (cTNM) and the pathological TNM 
(pTNM) status regarding the prognosis. Table 2 shows the 1- and 5-year survival rates 
based on cTNM status 14. Survival based on pTNM is better for each TNM stage 15. 
For instance, the 5-year survival increases from 61% to 67% and from 34 to 55% 
between cTNM and pTNM for stage IA and stage IIA, respectively 15. 
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Table 2. Clinical Staging of Lung Cancer and survival (adapted from Mountain CF) 14 
     Survival Rate (%)
Stage Tumour Node Metastasis General Description 1 Yr 5 Yr 
 
Non-small-cell lung cancer 
      
 
Local 
      
  
cIA 
 
T1 
 
N0 
 
M0 
T1 tumour: ≤ 3cm, surrounded by lung or 
visceral pleura 
 
91 
 
61 
  
 
cIB 
 
 
T2 
 
 
N0 
 
 
M0 
T2 tumour: > 3 cm, involving main 
bronchus ≥ 2 cm distal to carina; invading 
pleura; atelectasis or pneumopathy of  less 
than the entire lung 
 
 
72 
 
 
38 
  
cIIA 
T1 N1 M0 N1: involvement of ipsilateral peribronchial 
or hilar nodes and intrapulmonary nodes by 
79 34 
  T2 N1 M0 direct extension 61 24 
  
cIIB 
 
T3 
 
 
 
N0 
 
M0 
T3 tumour: invasion of chest wall, 
diaphragm, mediastinal pleura, pericardium; 
main bronchus < 2cm distal to carina;  
atelectasis or pneumonitis of entire lung 
 
55 
 
22 
 
Locally advanced 
      
  T3 N1 M0  56 9 
 cIIIA  
T1,T2,T3 
 
N2 
 
M0 
N2: involvement of ipsilateral mediastinal 
or subcarinal nodes 
 
50 
 
13 
  
 
 
cIIIB 
 
 
T4 
 
 
N0, N1, N2
 
 
M0 
T4 tumour: invasion of mediastinum, heart, 
great vessels, trachea, oesophagus, vertebral 
body, carina; separate tumour mass in the 
same lobe; malignant pleural effusion 
 
 
37 
 
 
7 
  
 
Any T N3 M0 N3. Involvement of contralateral (lung) 
nodes or any supracalvicular node 
32 3 
 
Advanced metastatic 
      
 cIV Any T Any N M1 Distant metastasis 20 1 
 
Small-cell lung cancer 
      
 
 
 
Limited disease 
   Evidence of tumour confined to ipsilateral 
hemithorax; can be encompassed by a single 
radiation port  
 
65 
 
15 
 Extensive disease    All other disease, including metastatic 
disease 
  
20 
 
1 
 
 
 12 
Non-small cell lung cancer (NSCLC) 
 
Non-small cell lung cancer constitutes about 80% of lung cancer cases and is divided 
in three major subgroups (Table 1). Squamous cell carcinoma in Norway accounts for 
30-50% of NSCLC with a declining incidence, and adenocarcinoma represents 25-
50% with a correspondingly increasing incidence. The same shift in histologic types 
is recognised in the rest of Europe and North America 16. The most likely explanation 
for this is the introduction of low-tar filter cigarettes causing deeper inhalation 
bringing the carcinogens more distant in the lungs and leaving the bronchioalveolar 
epithelium more exposed. Large cell carcinoma constitutes 5-15% of the cases.  
At diagnosis, about 20% of the patients have localised disease (stage I and II), 
40% are in locally advanced stage (stage IIIA and IIIB), and 40% have metastatic 
disease (stage IV). 
 
Surgery 
All patients considered technically and medically operable (stage I and II) should be 
offered surgery. The prognosis is fairly good in early disease. However, only about 
60% of patients with clinically detected small tumours without lymphatic spread 
(cIA) will survive for 5 years. The explanation to this is the early metastatic course of 
NSCLC and the underdiagnosis of lymphatic spread. On the other hand, the early 
metastasis justifies the use of adjuvant chemotherapy in early stage disease.  
Surgery in stage IIIA is more complex and controversial. Stage T3N1 is 
considered technical operable by most surgeons. However, surgery in N2 disease 
remains unclear, which indicate that patients should be treated within the context of 
randomised clinical trials. Preoperative chemotherapy seems promising, but warrants 
conclusive evidence in larger phase III trials 17,18. Patients not candidates for surgery 
should receive radical curative RT alone or with concomitant chemotherapy. The 
benefit of surgery after neoadjuvant chemotherapy (downstaging) in N2-disease 
versus neoadjuvant chemotherapy followed by radical RT is the main research issue 
in a large ongoing Nordic trial 19.  
Stage IIIB is considered inoperable, both technically and biologically. 
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Chemotherapy 
The most active cytostatic drugs in NSCLC are those of the platinum family: 
cisplatin, an alkylating drug which cross-links DNA, and carboplatin which is a less 
toxic cisplatin analogue. In combination with other drugs most studies suggest that 
carboplatin is as effictive as cisplatin. While etoposide and mitomycin C were most 
used in the 80s 20, today several “new drugs” like the taxans (docetaxel, paclitaxel), 
gemcitabine and vinorelbine are most often combined with cis- or carboplatin (Table 
3). The preferred combination is mainly based on the administration feasibility, 
toxicity, and cost-benefit evaluation. None of the new drug combinations have shown 
superiority compared to the other 21. The combination of carboplatin with vinorelbine 
or gemcitabine is most often used in Norway due to moderate costs and the feasibility 
of an outpatient administration. 
 
Table 3 Chemotherapy for NSCLC 
 
Drug 
 
Type of agent 
 
Major adverse effects 
 
Comments 
    
Platinum agents    
 
Cisplatin (Platinol) 
 
Atypical alkylator 
Nausea and vomiting, 
nephrotoxicity, ototoxicity, 
neuropathy, myelosuppression, 
electrolyte disorders 
 
Hydration required before and 
after administration 
 
Carboplatin (Paraplatin) 
 
Atypical alkylator 
Myelosuppression 
(trombocytopenia), nausea and 
vomiting (mild), neurotoxicity 
(rare), nephrotoxicity (rare) 
 
Dosage using AUC, less 
hydration 
 
Non-platinum agents 
   
 
Etoposide (Vepeside) 
 
Topoisomerase II inhibitor 
Myelosuppression, nausea and 
vomiting, stomatitis, diarrhea 
Stomatitis and diarrhea rare 
with normal dose 
 
Gemcitabine (Gemzar) 
 
Antimetabolite 
Myelosuppression, nausea and 
vomiting, diarrhea, edema, 
influenza-like syndrome, skin 
reaction 
 
Increased monitory of liver 
function necessary 
 
Pacliatxel (Taxol) 
 
Microtubuli inhibitor 
Myelosuppression, mucositis, 
peripheral neuropathy, 
hypersensitivity reaction, nausea 
and vomiting 
Requires pretreatment with 
dexamethasone, H2-inhibitor 
and antihistamine 
 
Docetaxel (Taxotere)  
 
Microtubuli inhibitor 
Myelosuppression, edema and 
fluid retention, mucositis, 
diarrhea, hypersensitivity 
reaction, nausea and vomiting 
Requires treatment with 
dexamethasone before during 
and after infusion 
Vinorelbine (Navelbine) Microtubuli inhibitor Myelosuppression, nausea and 
vomiting, phlebitis 
Mild vesicant 
 
Two-drug regimens with cis-/carboplatin as basis are superior to single-drug and not 
inferior to three-drug regimens 22,23. However, in a recent meta-analysis of phase III 
trials comparing cisplatin- and carboplatin-based combinations in advanced NSCLC, 
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a possible benefit in favour of a cisplatin combination was found, especially when 
cisplatin was combined with a novel agent 24. 
Compared to SCLC, NSCLC is less sensitive to chemotherapy. Nevertheless, 
there is considerably evidence that treatment with chemotherapy in advanced NSCLC 
patients with a reasonable good performance status (PS 0-1(2)), increases survival, 
improves health related quality-of-life (HRQOL) and reduces disease related 
symptoms 25.   
Although early phase III trials with adjuvant chemotherapy after completely 
resected non-small tumours failed to show effect 26,27, subsequent larger trials have 
shown evidence of benefit from adjuvant chemotherapy 28-32. There is now consensus 
that radically operated patients should be offered adjuvant chemotherapy if considered 
physically fit 33,34. 
Whether chemotherapy has a role in the neoadjuvant setting before surgery 
remains to be determined. This treatment principle has shown to benefit in localised 
stage IB and stage II disease 35, as well as in cN2 disease (stage IIIA) 17,18,36,37. 
Subsequent studies have, however, not been able to reproduce these results 35,38.   
Table 4 gives an overview of chemotherapy effect in NSCLC. 
 
Table 4.  Effect of Chemotherapy in Non-Small Cell Lung Cancer 
    
Stage 
Treatment 
intention 
 
No of courses
 
Main effect 
cIB-IIIA - adjuvant curative 3-4 4-8 % improved 5-year survival 
cIB-IIIA - neoadjuvant curative 2-3 Downstaging with improved rate of surgery 
   Survival benefit still questionable 
   Improved 1- and 2-year survival 
cIII & cIV palliative 3-4 Improved HRQOL 
   Improved symptom control 
 
 
Radiotherapy 
Radiotherapy (RT) is widely used in the treatment of NSCLC. A curative result with 
RT is feasible in stage I and II disease not candidates for surgery, and in localised 
stage III disease. The RT is given by use of a three-dimensional conformal 
radiotherapy (3D-CRT) planning system to secure a homogenous dose to the tumour 
area and sparing of normal lung tissue. In localised stage I and II disease, a 5-year 
survival of about 20-30% is achievable by RT only 39,40. The treatment is most often 
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given with a conventional fractionation schedule, but the same 5-year survival in early 
disease has also been attained with a hypofractionated technique 41. Stereotactic RT 
using a body frame and high dose external RT in few fractions yields a high degree of 
local control and a fairly good one-year survival. Long-term survival with this 
technique is still not reported 42.  The possibility of eradicating a tumour with RT is 
clearly correlated to the tumour volume 43.  
Locally advanced inoperable disease (stage III) is a more heterogeneous 
group. Radical RT can be offered to patients with favourable prognostic factors, while 
patients with poor prognostic factors should be treated with a palliative intent.  
Conventional radiotherapy given with a curative intent can produce long-term 
survival with a 5-year survival rate of 5% 44,45. With the introduction of 3D-CRT in 
the 80s it was possible to treat the tumours with higher dose while reducing the side 
effects, especially related to the total lung volume and spinal irradiation. However, an 
increased long-term survival has not ben proven 46.  
Of patients failing treatment with a curative intent, about one third will relapse 
locally, one third will develop distant metastasis, and one third will develop both. 
Since lack of local control, explained by rapidly proliferating clonogenic cells, is a 
major problem, accelerated radiotherapy has been tested. Accelerated treatment gave 
a longer 2- and 3-year survival, but the 5-year survival rate was not increased 47,48.  
Enhancement of the radiotherapeutic effect can be achieved by use of 
concomitant chemotherapy radiosensitizing the tumour 49,50. Cisplatin is most used, 
but other drugs are also candidates 51. An ongoing randomised trial from the 
Norwegian Lung Cancer Study Group (NLCG) 52 is testing docetaxel 20 mg/m2 once 
weekly with 60 Gy 3D-CRT compared to 60 Gy 3D-CRT alone. Since distant 
metastasis is a major problem, the logic approach to localised inoperable stage III 
disease would be to add systemic chemotherapy to treat subclinical micrometastasis 
either up front or after completed radiotherapy. This approach has been tested with 
two to three induction chemotherapy courses before radiotherapy. No gain in long-
term survival has so far been documented 53,54. The treatment is feasible, but yields 
increased toxicity 55,56.  
When the treatment intention is palliative, either in stage III disease with 
negative prognostic factors or stage IV disease, the treatment can be simplified with 
the use of a short course or hypofrationated radiotherapy 57,58. However, in stage III 
patients with good performance status (PS 0-1), a protracted higher dose palliative 
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radiotherapy schedule yields more long-time survivors than hypofractionated 
schedules 59-61.  
The effect of RT in NSCLC in different stages is summarised in Table 5. 
 
Table 5.  Treatment Effect of RT in Non-Small Cell Lung Cancer  
    
Stage 
Treatment 
intention 
 
Technique 
 
Dose (Gy) 
 
1 year (%) 
 
5 year (%) 
cI curative 3D-CRT 55-70 75 20-30 
  Stereotactic 10-15 Gy x 3 52 not reported 
cII curative 3D-CRT 55-70 70 20 
  conventional ≥ 60 40-50 5 
  3D-CRT ≥60   50-60 5 
cIII (positive prognostic factors) curative CHART/accelerated 54-70 55 5 
  3D-CRT + concurrent  ≥60 55-70 5-8 
  Neoadj + 3D-CRT + concurrent ≥60  60-70 5-8 
cIII (negative prognostic factors) palliative Simple A-P 39-50 25 3-4 
  Simple A-P 10-17 25 0 
cIV palliative Simple A-P 10-17 25 0 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
. 
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Small cell lung cancer (SCLC)  
Small cell lung cancer constitutes 20% of all lung cancer cases (Table 1). Forty per 
cent of the patients are diagnosed with LD-SCLC, while 60% present with ED-SCLC. 
 
Surgery 
Due to an aggressive tumour growth, nearly all these cancers have spread either to 
regionally lymph nodes in the mediastinum (N2/N3) or distant metastasis to other 
organs at time of diagnosis. Very few SCLC tumours are diagnosed at an early 
enough stage where surgery may be possible (< 5%). However, if such a situation 
occur (peripheral T1N0 or T2N0 tumours), radical surgery should be performed 62,63, 
followed by adjuvant chemotherapy 64. 
  
Chemotherapy 
SCLC is highly sensitive to chemotherapy 65. The majority will initially achieve a 
complete or good partial response on combination chemotherapy, but most tumours 
will relapse and the patients will succumb from chemotherapy-resistant disease. 
Long-term survival is achievable in LD-SCLC with 15% 5-year survival, whereas 
long-term survival is uncommon in ED-SCLC patients 66.  
During the 70s, combination chemotherapy with the CAV regimen 
(cyclophosphamide, adriamycin, vincristine) became standard treatment in SCLC 67. 
During the following decade, combination of cisplatin and etoposide (EP-regimen) 
revealed favourable efficacy, although randomised phase III studies failed to prove a 
definitive survival benefit when compared to CAV 68,69. Nevertheless, the EP-regimen 
became the most used chemotherapy regimen for SCLC, mostly due to better 
feasibility with concurrent chest irradiation 70. The superiority of the EP-regimen is 
subsequently shown in two meta-analysis 71,72. However, the efficacy in ED-SCLC is 
more limited leaving anthracyclin-containing regimens still an option in this group.  
Since SCLC is highly sensitive to cytostatic drugs, intensified chemotherapy 
would be a logic approach. This can be done in different ways; 1) higher dose with 
use of granulocyte colony-stimulation factor (G-CSF); 2) adding more drugs (three- 
or four-drug combinations); 3) alternating regimens; or 4) high dose with bone 
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marrow rescue. However, such treatment options induce higher response rates, but no 
improvement of survival 73,74. In a study performed by NLCG, adding paclitaxel to 
cisplatin and etoposide in LD-SCLC, survival was not improved 74.  
New drugs have been tested in SCLC, but none has been found clearly 
superior to older drugs or drug combinations 75. One phase III trial, strictly looking at 
ED disease comparing cisplatin and etoposide to cisplatin and irinotecan has shown 
significant superiority in favour of the irinotecan arm 76. A phase III trial from NLCG 
comparing carboplatin/etoposide versus carboplatin/irinotecan in the same patient 
group is recently completed, waiting for the results 77. A recent publication, however, 
does not support the superiority of cisplatin-irinotecan combination in ED-SCLC 78. 
 
Radiotherapy 
When the tumour and adjacent enlarged lymph nodes can be included in a single 
radiation port, the disease is defined as LD-SCLC, in contrast to ED-SCLC. This is a 
pragmatic differentiation in order to select treatment combined with or without RT. 
During the late 80s, the addition of thoracic radiotherapy (TRT) 79 and prophylactic 
cranial irradiation (PCI) 80,81 in LD-SCLC patients resulted in a significant survival 
benefit and have become part of routine treatment. In contrast, TRT and PCI do not 
increase survival in ED-SCLC patients.  
 TRT should be delivered concurrently with chemotherapy and early 
administration is better than delayed 82,83. There is also evidence for better results with 
accelerated (twice daily) compared to once daily TRT. The best results reported are 
achieved with accelerated TRT given concurrently with the first cycle of 
chemotherapy 84 achieving a 26% 5-year survival in the accelerated arm. However, 
these results have not been reproduced by others. A new study from NLCG initiated 
in 2005, will compare accelerated TRT (1.5 Gy/twice daily/30 fractions) to the 
Norwegian hypofractionated standard (2.8 Gy/15 fractions) in LD-SCLC. TRT are to 
be started early after the second chemotherapy course (week 4) using a 3D-CRT 
technique 85.  
 An overview of the treatment principles in SCLC is outlined in Table 6. 
 
 
 
 19
Table 6.  Treatment Principles in Small Cell Lung Cancer  
    Survival (%) 
  Stage Surgery Chemotherapy Radiotherapy 1-year 5-year 
T1/T2N0 Yes Adjuvant No 70 40-50 
 
LD-disease 
 
No 
 
EP-regimen 
TRT 40-50 Gy concurrent with chemotherapy 
- early start of TRT 
- accelerated TRT (?) 
- PCI in complete or good partial responders 
 
65 
 
15 
 
ED-disease No EP-regimen 
CAV/CEV-regimen
Not routinely 15 1-2 
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Prognostic factors and the clinical decision 
making process 
At diagnosis, most lung cancer patients have advanced disease and are beyond the 
possibility of cure. Even though the treatment intention for these patients is palliative, 
the beneficial effect of cytotoxic drugs and/or radiotherapy is well documented. The 
benefit on survival seems to be closely related to individual patient characteristics, 
often classified as prognostic factors for survival. Some common prognostic factors 
for survival are universal for lung cancer and should be used routinely in the clinical 
decision-making process.  
The most important prognostic factors are stage of the disease, performance 
status (PS), (WHO-scale, Karnofsky scale), and weight loss.  
 
Table 7. Performance status (PS) 
Description Karnofsky Scale KPS score WHO score Description WHO Scale 
Normal, no complaints, no evidence 
of disease 
100 0 Able to carry out all normal 
activity without restriction 
Able to carry on normal activity, 
minor signs or symptoms of disease. 
Normal activity with effeort, some 
signs and symptoms of disease. 
90 
 
80 
 
1 
 
Restricted in physically strenuous 
activity, but ambulatory and able 
to carry out light work 
Cares for self, unable to carry on 
normal activity or do active work. 
Requires occasional assistance, but is 
able to care for most personal needs. 
70 
 
60 
 
2 
Ambulatory and capable of all 
self-care, but unable to carry out 
any work up and about more than 
50% of  waking hours 
Requires considerable assistance and 
frequent medical care. 
Disabled, requires special care and 
assistance. 
50 
 
40 
 
3 
 
Capable of only limited self-care; 
confined to bed or chair more 
than 50 % of waking hours 
Severly disabled, hospitalisation 
indicated; death not imminent.  
Very sick, hospitalisation indicated; 
death not imminent. 
Moribund, fatal process progressing 
rapidly. 
30 
 
20 
 
10 
 
 
4 
 
Completely disabled; cannot 
carry out any self-care; totally 
confined to bed or chair 
 
Prognostic factors in NSCLC 
Disease stage is the dominant prognostic factor, since there is no available curative 
treatment if the tumour has spread outside the chest. Within each stage there is a 
correlation between tumour size, N-status and prognosis (Table 2). Also within each 
classified T-stage the tumour size correlates with the prognosis. The possibility of 
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eradicating the tumour, either with TRT alone or with TRT combined with 
chemotherapy, seems to be at a maximum tumour diameter of 6-8 cm 43, 86.  
PS is the second most important prognostic factor and should be evaluated 
prior to treatment decision. NSCLC patients with PS 3-4 should not routinely receive 
tumour specific treatment, but be assigned to best supportive care (BSC) 25,87,88. 
Chemotherapy for these patients may give more toxicity than clinical meaningful 
benefit. PS 2 patients experience increased toxicity and have shorter survival than PS 
0-1 patients, indicating that these patients should possibily be chemotherapy treated 
only within clinical controlled trials 25. 
Weight loss is common and is most often categorised according to the normal 
body weight before diagnosis and to the time interval over which the weight loss have 
developed (none versus < 5-10 % versus ≥ 10 % of normal body weight) over the last 
3-6 months. Weight loss is a consistent and strong prognosticator 25,87,88. A weight 
loss ≥ 10 % over the last 3 months is a very strong negative prognostic factor, and 
most patients should probably be treated with a palliative intent regardless of other 
prognostic factors. 
 
Prognostic factors in SCLC 
Since SCLC is highly sensitive to chemotherapy, a clinical meaningful benefit from 
chemotherapy may be achieveable also in PS 3-4 patients. All patients with a 
diagnosis of SCLC should therefore be considered for tumour specific treatment.  
Otherwise, disease stage (LD versus ED) is the strongest prognosticator 89,90. 
In a large study from NLCG, extent of disease and PS were revealed as the most 
powerful prognosticators 91. LD-SCLC patients with favourable prognostic factors 
should be treated with a curative intent. Although some long-term survivors with ED-
SCLC appear, the treatment intention in these patients is primarily palliative.  
 
Table 8.  Prognostic Factors and Treatment Principles in Lung Cancer 
  Curative intent (Surg, CT, 3D-CRT) Palliative intent  (CT, RT) Best  supportive care 
 stage PS Weight loss Tumour size PS Weight loss Tumour size PS Weight loss Tumour size 
 I 0-1 < 5% any 2 5-10% any 3-4 any any 
NSCLC II 0-1 < 5% any 2 5-10% any 3-4 any any 
 III 0-1 < 5% < 8-9 cm 0-2 any >10 cm 3-4 any any 
 IV    0-2 any any 3-4 any any 
SCLC LD 0-2 < 5-10% any 3-4 any any    
 ED    0-4 any any    
Surg = surgery, CT = chemotherapy 
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Assessment of palliative treatment 
Success in cancer treatment has traditionally been measured in terms of cure rate, 
increased survival and tumour response. However, when the treatment intention is to 
palliate, the improvement of symptoms and quality-of-life should be the main goals 
92,93. Oncologic palliation is defined as treatment with surgery, radiotherapy, hormone 
therapy, chemotherapy or other tumour modulating treatment given as a single 
modality or combined in patients who cannot be cured. These treatments relieve 
symptoms by reducing tumour burden and may sometimes prolong life. In addition 
symptomatic treatment for pain with opiods, 5HT-3 antagonists for emesis, and 
megesterolacetate for weight loss is essential for lung cancer patients. For all 
palliative treatments, the benefits must outweigh their risks and burdens 94. 
Treatment-related side effects should always be detected and registered 
systematically. Criteria for classifying side effects are defined and implemented in 
most clinical trials (WHO Toxicity Criteria, NCI Common Toxicity Criteria) and 
reported as important end points. In contrast, the concept of quality-of-life is complex 
and represents more than toxicity and side effects. Quality-of-life is perceived as a 
multidimensional phenomenon and is defined in different ways, most often by a 
psychosociological definition, or in a medical/health-related definition (HRQOL). 
When assessing HRQOL, the use of patient self-assessment questionnaires is 
advocated 93,95.  
 
Questionnaires 
Several questionnaires for use in cancer patients have been developed and introduced 
in cancer research over the last two decades. These include the Functional Living 
Index Cancer (FLIC) 96, the Toronto Scale 97, the Rotterdam Symptom Checklist 
(RSCL) 98, the Cancer Rehabilitation Evaluation System (CARES) 99, the Functional 
Assessment of Cancer Therapy Scale (FACT) 100 and the EORTC Core Quality of 
Life Questionnaire (EORTC QLQ C-30) 101. These instruments have been validated 
and found suitable in large-scale clinical trials.  
The EORTC QLQ C-30 questionnaire is a brief core questionnaire designed 
for use in the general cancer patient in order to detect common symptoms and 
problems. Moreover, additional diagnosis-specific modules have been developed in 
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order to intercept symptoms related to a specific tumour type 102. One of these is the 
lung cancer module, QLQ LC-13 103. This module together with the core 
questionnaire has been validated in clinical trials in both NSCLC and SCLC. This 
instrument is widely used in the Nordic countries. All randomised lung cancer trials 
performed by NLCG during recent years, have used these questionnaires as the main 
method for assessing HRQOL.  
 
Physician-performed assessment of palliative 
benefit 
In general, physicians and other caregivers have a tendency to overestimate the 
benefit of a treatment and to underestimate the side effects of a given treatment 104-106. 
Since HRQOL is a multidimensional subjective phenomenon, comparison between 
patient- and physician-rated estimation of HRQOL are frequently restricted to 
compare more categorical variables like PS, pain and other disease-specific 
symptoms. The level of agreement between patients and their observers is 
investigated both at the group level and at the individual patient level. At the group 
level there is often a reasonably good patient-observer agreement 107,108, while this is 
not the case at the individual patient level 109,110. 
 Specific disease related symptoms can be assessed by clinicians if these 
symptoms are well defined in advance and scored according to a categorised scale. 
The studies from the Medical Research Council (MRC) in the United Kingdom 
pioneered the use of a systematic clinician-assessed evaluation of symptoms together 
with patient-rated self-assessment of symptoms and HRQOL 57,58. These studies used 
a 4-point rating scale (none, mild, moderate, severe) for different disease-specific 
symptoms. Provided a systematic completion of symptom scales by the clinicians 
during the follow-up period, valuable information about the palliation of symptoms is 
achievable. However, the gold standard should nevertheless be patient-reported 
information, while observer assessments will be complementary and can be used for 
conformation 111.  
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Clinical trials 
Why do clinical trials? 
Progress in the treatment of patients is based on observation of effects and side effects 
following a specific intervention. A planned intervention in patients with well-defined 
baseline characteristics and with systematic collection of outcome data, is defined as a 
clinical trial. A clinical trial is a prospectively performed investigation, and properly 
conducted trials provide the only reliable scientific basis for evaluating new treatment 
strategies 112.  
 There are several good reasons for treating cancer patients within clinical 
trials. Patients in trials will be offered high quality treatment and high quality follow-
up. It is suggested that physicians who participate in clinical trials take better care of 
their patients 113. It is unclear if this is because participation in protocols is a form of 
continuing medical education, or if better clinicians are drawn to clinical trials 
participation.  
 According to the criteria’s from the Catalan Agency for Health Technology 
Assessment, a system for categorisation of scientific evidence in medicine is 
proposed. This system is approved in Norway through the National Cancer Plan 
(NOU 1997) 114. Meta-analysis of randomised trials using analysis of individual 
patient data is considered the ultimate level of evidence, level I. Level II is defined as 
large sample randomised controlled trials, whereas small sample randomised trials are 
categorised as level III. Non-randomised comparative studies are rated level IV 
evidence. According to the NOU criteria, two large phase III trials are required before 
a treatment change in cancer patients is recommended, whereas in small groups where 
a limited number of patients may prevent phase III studies, five non-randomised 
comparative studies with equivalent results are accepted as evidence 114. 
 
Randomised clinical trials 
The gold standard in clinical research is the randomised controlled trial (RCT) 112. 
RCTs are the most rigorous way of determining whether a cause-effect relation exists 
between treatment and outcome, and for assessing the effectiveness of a treatment 115. 
This technique provides a random allocation to the intervention groups, thereby 
 25
avoiding selection bias regarding treatment arms. The randomisation procedure 
secures that the intervention groups will be similar with respect to baseline prognostic 
factors, provided large enough patient groups. Ideally, all patients included in a phase 
III controlled clinical trial should be analysed, even though the planned treatment was 
not completed or started (intention-to-treat analysis). The size of a phase III study 
should be based on an estimation of difference in predefined outcome parameters 
between the intervention groups.  
 
Comparative clinical trials 
The selection bias problem in a study population is avoided by a randomisation 
procedure. This is not the case for a non-randomised comparative study, thus the 
findings should therefore be interpreted with caution. However, a non-randomised 
trial is nevertheless valuable in clinical research provided a rigorous registration of 
outcome effects and events, especially if the study population is large 116.  
Well-designed RCTs have strict inclusion criteria in order to achieve 
appropriate and comparable intervention groups. The inclusion criteria will, however, 
often expel a large part of the relevant patient population, leaving a limited part which 
fulfils the inclusion criteria to be randomised 117,118. Even though, results from large 
and well-designed RCTs will often be extrapolated to be normative for the entire 
population of interest. On the other hand, advocates for non-randomised clinical trials, 
claim that the accrual selection is lower and the study may more accurately reflect the 
population of interest 119.  
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Aims and objectives 
The purpose of the present thesis is to improve the treatment for patients with 
advanced lung cancer by performing multicentre randomised clinical trials.  
 
Small cell lung cancer - chemotherapy trial  
1. Background: Combination chemotherapy is the primary treatment modality in 
SCLC patients. When the given study was planned, some evidence existed that 
cisplatin-containing chemotherapy is perhaps more effective than anthracyclin-
containing chemotherapy in prolonging survival, while the latter was considered 
the treatment of choice at that time.  
Research question: Is cisplatin-based chemotherapy (EP-regimen; etoposide, 
cisplatin) superior to anthracyclin-based chemotherapy (CEV-regimen; 
cyclophosphamide, epirubicin, vincristin) as first-line treatment? 
2. Background: CEV- and EP-chemotherapy are considered non-cross resistant in 
SCLC. Some studies indicate that EP-chemotherapy in previously CAV treated 
patients is more effective regarding survival than the reverse sequence. A 
crossover study of the randomised study population (1) at relapse was performed.  
Research question: Is EP-chemotherapy superior in CEV-treated patients, 
compared to the reverse sequence, as second-line treatment?  
 
Non-small cell lung cancer - palliative TRT-trial  
1. Background: Palliative thoracic radiotherapy (TRT) is considered to be beneficial 
in patients with advanced NSCLC. No consensus regarding total dose and 
fractionation exists.                                                                                        
Research question: Is hypofractionated TRT (8.5 Gy x 2) comparable with high 
dose fractionated (2.8 Gy x 15; 2.0 Gy x 25) palliative TRT concerning effect on 
symptoms, HRQOL and survival? 
2. Background: Patients with advanced NSCLC with none or minimal symptoms 
(NS) will often be treated with palliative TRT up front before symptoms develop.                               
Research question: Will NS patients given immediate TRT achieve maintained 
HRQOL and prevention of tumour-related thoracic symptom development? 
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Material and methods 
Setting 
This thesis is based on two large study populations, the first one in SCLC patients 
(paper I and paper II) and the second one in advanced NSCLC patients (paper III and 
paper IV). The studies were performed as national multicentre trials with patients 
included from all health regions in Norway.  
Both studies were performed within the context of the Norwegian Lung 
Cancer Study Group. This group was established by Erik Thorud in the 80s with the 
aim of improving the treatment and care of lung cancer patients and to undertake 
clinical research. The group is multidisciplinary with physicians from different 
specialities (oncology, pulmonology, surgery, epidemiology, pathology, radiology). 
One major task for this group is to initiate, administer and publish national lung 
cancer trials.  
 
Study population and design, paper I 
Patients with SCLC were the target population for this study. Both LD-SCLC and 
ED-SCLC patients were included. Verified histology and PS 0-2 were the main 
inclusion criteria. 440 patients were included in the period from January 1989 to 
August 1994 from 25 hospitals. Four patients were ineligible due to incorrect 
diagnosis (NSCLC) leaving 436 patients in the study. 214 patients were classified 
with LD-SCLC and 222 patients with ED-SCLC. All patients were treated with five 
chemotherapy courses. LD-SCLC patients received additional TRT between course 
three and four. Patients with LD-SCLC disease obtaining complete remission after 
induction chemotherapy were recommended PCI. From November 1989 to December 
1993 the patients were invited to participate in a HRQOL part of the study. The 
inclusion criteria are described in paper I. 
The patients were randomised to two different chemotherapy regimens 
consisting of: A) etoposide 100 mg/m2 followed by cisplatin 75 mg/m2, both 
intravenously (IV) on day one, with oral etoposide 200 mg/m2 on days 2-4 (EP-
regimen), and B) epirubicin 50 mg/m2, cyclophosphamide 1000 mg/m2, and 
vincristine 2 mg, all IV on day one (CEV-regimen). The EP-regimen was considered 
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the experimental treatment arm. 218 patients were allocated to the EP-regimen and 
218 patients to the CEV-regimen. The primary end-point was survival. Provided no 
difference in survival, toxicity and HRQOL should be decisive for treatment 
recommendations. These were therefore considered as secondary end-points.  
  
Study population and design, paper II 
At the time when the SCLC study was planned, CAV- and EP-regimen were 
acknowledged as non-cross resistant regimens. Some evidence existed that EP 
chemotherapy in previous CAV-treated patients could be more effective than the 
reverse sequence. According to the protocol, the patients were recommended the other 
regimen at relapse if they were considered for second-line chemotherapy. Among 
patients with quality assured follow-up information regarding recurrence and 
retreatment, 286 patients were diagnosed with relapse. Of these, 120 patients were 
retreated with chemotherapy, 52 with crossover CEV chemotherapy, 56 with 
crossover EP-regimen, and 12 with the previous induction regimen. A comparison 
between the two crossover regimens was performed. In addition, the data gave the 
opportunity to compare the effect of actively chemotherapy-retreated patients 
(N=120) with those who were not (N=166).  
 
Study population and design, paper III 
Patients with advanced stage III or stage IV NSCLC disease, not considered for 
curative treatment, were included in this study. The patients should have disease 
related airway symptoms or with centrally located tumours threatening the central 
airways. The patients should be able to understand and fill out HRQOL 
questionnaires. All established radiotherapy centres in Norway participated in the 
study accruing patients from December 1993 through September 1998. One centre 
alone (The University Hospital in Trondheim, Department of Oncology) contributed 
with 52% of the patients. In total, 421 patients were included in the trial. The 
inclusion criteria are described in paper III.  
The study was a RCT of three different TRT strategies evaluating the 
palliative effect on tumour-related symptoms from central airways. The objectives 
were to address whether a hypofractionated schedule (17 Gy/2 fractions, Arm A) 
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(N=143) was comparable to the standard fractionation in Norway (42 Gy/15 fractions, 
Arm B) (N=140). Moreover, our standard regimen had for several years been disputed 
as an inferior regimen. Therefore, a third arm (50 Gy/25 fractions, Arm C) (N=124) 
was incorporated in the study. The primary end-points were patient-assessed and 
clinician-assessed symptom relief of dyspnoea, cough and hemoptysis, while survival 
and the other domains in the HRQOL questionnaire were secondary end-points. Due 
to an anticipated limited survival of the majority of the patients, the period up to week 
22 from study entry was defined as the period of primary interest.  
 
Study population and design, paper IV 
At study entry, the patients included in the palliative TRT study were stratified 
according to symptoms present (S-patients) or with none or minimal symptoms (NS-
patients). This stratification was based on the clinical examination by the responsible 
physician on site prior to randomisation. 407 patients were eligible for the study, 107 
categorised as NS-patients and 300 as S-patients. Nearly all eligible patients (N=395; 
97%) accepted to participate in the HRQOL part of the study. Since the compliance of 
the questionnaires was very high, the HRQOL data could be explored longitudinally 
to assess the effect of immediate palliative TRT in NS- versus S-patients in a non-
randomised comparative fashion.  
 
The EORTC QLQ-C30 and LC-13 questionnaire 
This questionnaire is developed by the European Organisation for Research and 
Treatment of Cancer 101,103. The questionnaire incorporates five functional scales 
(physical, role, emotional, cognitive, social), three symptom scales (fatigue, 
nausea/vomiting, pain), a global health and overall quality-of-life scale, and five 
single items; dyspnoea, appetite loss, sleep disturbance, constipation and diarrhea, and 
financial impact of disease and treatment (see appendix for the entire questionnaire). 
The QLQ-LC13 module contains disease specific items for measuring dyspnoe, 
cough, hemoptysis, mucositis, dysphagia, peripheral neuropathy, alopecia, pain, and 
analgesic consumption/effect (see appendix). All scales and single-item were linearly 
transformed to a scale from 0 to 100. The scoring procedure followed the EORTC 
QLQ C-30 Scoring Manual 120. A high score for the functional scales and the global 
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health scale represents a high/healthy level of functioning, whereas a high score for 
the symptom scales represents a high level of symptomatology/problems.  
In both RCTs the first questionnaire was delivered to the patient from the 
responsible physician at the time of receiving informed consent. Later questionnaires 
were mailed from the data center to the patients at 2, 6, 14, 22, 30, 38, 46, and 54 
weeks from the start of treatment. A reminder was sent to patients not returning the 
questionnaire within 2 weeks. Patients still non-compliant after one reminder received 
no further questionnaires.    
 
Outcome assessments 
Prospective assessments of HRQOL and symptoms are central in paper I, paper III, 
and paper IV in this thesis.  
Longitudinally HRQOL data will often be presented graphically and can be 
visualised in several ways: 1) reporting the proportion of patients exceeding a certain 
level (cut point; categorical scale), 2) mean or median scores of all scales and all 
items, and 3) individual data points 121. Assessing patients exceeding a specific value 
or level will reduce the study population and can therefore attribute to a selection bias. 
Using mean or median scores secures studying all patients, but a concealing effect of 
the inter-individual variability will occur. Individually data plots may be confusing 
and difficult to interpret. According to common recommendations, the method of 
presenting mean scores was chosen in this thesis due to a straightforward 
interpretation if the patient number between the intervention groups is balanced and 
fair-sized.  
In paper III the HRQOL data were also explored using the method of patients 
exceeding score ≥ 2 (mild) at baseline and the percentage of these patients achieving 
an improvement, defined as at least one step change in the better direction on the 4-
point rating scale, following treatment. This was performed for the primary end-points 
cough, dyspnoea and hemoptysis.  
A method of presenting change in mean scores from baseline to different 
assessment times is easy to understand and interpret 122. This technique was explored 
in the palliative TRT study (paper III), but gave essentially the same results as using 
mean scores and was consequently not presented in the publication. 
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A fundamental problem concerning the interpretation of longitudinal HRQOL 
data is the patient compliance and the patient attrition 123,124. Patient non-compliance 
will generate missing questionnaires and incomplete data. This occurs more 
frequently in palliative clinical trials than in curative treatment trials. Patients with 
progressive disease and severe disease-related symptoms have a tendency of not 
fulfilling the questionnaires, generating questionnaire completion from the healthiest 
patient population. This may introduce a selection bias and render HRQOL scores too 
“good”, and not representative for the patient population. Techniques for handling 
missing data have been implemented and advocated, but there is no widely accepted 
consensus 125. The best way to overcome this problem is to achieve a substantially 
high compliance rate in the study population. Patients’ compliance of questionnaires 
should therefore always be reported when patient self-assessment methods are used. 
The evaluation of HRQOL in this thesis was explored at group level and based 
on mean scores at each assessment time calculated in all patients with completed 
questionnaires. A difference in HRQOL of five to 10 points has been considered as 
minor changes and of uncertain clinical relevance, while a change of 10 to 20 points 
represents a moderate to major change 126,127. Thus a difference of 10 points or more 
has been regarded as clinically significant at group levels.  
 
Clinician assessment of symptoms was central in the TRT study (paper III). 
This was performed for the primary end-points cough, dyspnoea and hemoptysis and 
used as a confirmatory method. Moreover, clinician-assessment of predefined 
categorised symptom development over time was essential also in paper IV. In both 
papers the system from the Medical Research Council was adopted 57,58 using a 4-
point rating scale (none, mild, moderate, severe) addressing cough, hemoptysis and 
other disease-related symptoms, and a 6-point scale addressing dyspnoea. In paper IV 
the patients were evaluated at different follow-up times (week 2, 6, and 14) after 
completed TRT and the data were compared to baseline values.  
 
Survival was defined as the primary end-point in paper I and II, and as a 
secondary end-point in paper III. In paper II survival was the only end-point in a non-
randomised comparison between two crossover treatment groups. Paper IV compared 
HRQOL between two different stratified groups without survival as an end-point 
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since the original exploration revealed no difference in survival according to the 
randomly assigned treatment arms (paper III).  
A summary of end-points and assessment methods according to study is 
shown in Table 9. 
 
Table 9. End-points and assessment methods  
 Primary 
end-points 
Secondary  
end-points 
Primary assessment methods Secondary assessment methods 
Paper I Survival 
 
HRQOL Survival using the method of 
Kaplan-Meyer 
EORTC C-30 + LC-13 
questionnaires  
Paper II Survival 
 
 Survival using the method of 
Kaplan-Meyer 
 
Paper III Symptom relief of  
dyspnoea, cough, 
hemoptysis 
1)HRQOL 
2) Predefined categorised 
symptoms 
3) Survival 
 
EORTC C-30 + LC-13 
questionnaires evaluating  the 
primary symptoms 
 
1) EORTC C-30 + LC-13 
questionnaires evaluating the other 
domains 
2) Clinician assessed effect on 
primary symptoms 
3) Survival using the method of 
Kaplan-Meyer  
Paper IV HRQOL Predefined categorised 
symptoms 
EORTC C-30 + LC-13 
questionnaires 
Clinician assessed effect on 
predefined symptoms 
 
Randomisation centres and data quality 
The Cancer Research Trial Office at the Norwegian Radium Hospital served as the 
randomisation centre and data management office for the SCLC study (paper I and 
paper II), while The Cancer Research Trial Office at the University Hospital in 
Trondheim handled the TRT study (paper III and paper IV). In both studies the 
HRQOL questionnaires were mailed from the data centre to the patients on identical 
time schedules (week 2, 6, 14, 22, 30, 38, 46, and 54). The baseline questionnaires 
were delivered to the patients by the physician’s during the process of receiving 
informed consent and thereafter sent to the trial office.  
Baseline clinical data and clinical information after fixed follow-up times were 
collected prospectively from the physicians. Reminders were sent to responsible 
clinicians in cases where forms were missing.  
Attempting to increase the data quality, a retrospective review of the medical 
records was performed in the SCLC study in patients recruited from major centres 
(Central Hospital in Østfold-Fredrikstad, Ullevål University Hospital, University 
Hospital in Bergen-Haukeland, Norwegian Radium Hospital, University Hospital in 
Trondheim, and University Hospital in Tromsø). These centres were responsible for 
348 of 436 eligible patients (80%).  
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In the TRT study, a retrospective review of the medical records was carried 
out in all patients.  
 
Statistics 
Survival was calculated from randomisation date using the Kaplan-Meyer product-
limit method with the log-rank test applied for comparison of survival 128,129. All 
survival analyses were calculated using the intention-to-treat principle. A complete 
follow-up of survival status was secured in all patients via the national death registery. 
Survival status was projected to 5-year and 3-year in the SCLC and TRT study, 
respectively.   
Due to large sample sizes and a randomised design, a normal distribution of 
baseline demographic and clinical patient characteristics was anticipated. Comparison 
between categorical baseline and treatment variables were analysed using parametric 
tests like Pearson’s chi-square tests or Fischer’s exact test. A level of P<0.05 was 
considered statistical significant. 
 In contrast, the multiplicity and complexity of HRQOL data do not ensure 
normative distribution. A non-normative distribution will most often be the case, 
especially in longitudinal studies due to attrition and missing data. Non-parametric 
tests are therefore recommended. HRQOL measurements between the treatment 
groups were analysed either with the Mann-Whitney U test for two independent 
samples (paper I and paper IV) or the Kruskal-Wallis test for several independent 
samples (paper III). In general, analysis of HRQOL data entails a large number of 
comparisons and repeated testing. Hence, the conventional criterion of statistical 
significance is not advisable. Therefore a P-value of <0.01 was considered necessary 
for statistical significance. However, the magnitude of observed differences must also 
be considered before interpretation. A consistency between several domains at 
different assessment times should also be exposed before clinical significance can be 
drawn 123.  
In one paper (paper II) exploration of possible prognosticators for survival was 
performed. Possible prognostic indicators were first tested for significance in 
univariate analyses using the method of Kaplan-Meier. Variables reaching statistical 
significance (<0.05) in the univariate analysis were tested in the multivariate analysis 
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using the proportional hazards model of Cox 130. Probability for forward stepwise 
entry and removal was set at 0.05 and 0.10, respectively.  
All analyses were done by SPSS for Windows.  
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Results and summary of papers 
 
Paper I 
Cisplatin and Etoposide Regimen Is Superior to Cyclophosphamide, Epirubicin, and 
Vincristin Regimen in Small-Cell Lung Cancer: Results From a Randomized Phase III 
Trial With 5 Years’ Follow-Up. 
 
This paper describes the hitherto largest performed RCT comparing an anthracyclin 
containing regimen (CEV-regimen) (cyclophosphamide (C), epirubicin (E), vincristin 
(V)) versus etoposide (E) and cisplatin (P) (EP-regimen) in SCLC. In total, 436 patients 
were studied. Stratification was performed for extent of disease. 214 patients had LD-
SCLC and 222 patients ED-SCLC. Survival analysis revealed a significant benefit in 
favour of EP chemotherapy with median survival of 10.2 versus 7.8 months in the EP 
and CEV arm, respectively (P=0.0004). However, this benefit in survival was 
restricted to the LD-SCLC patients with median survival of 14.5 versus 9.7 months in 
the EP and CEV arm, respectively (P=0.001). In ED patients, a trend in favour of EP-
chemotherapy with median survival of 8.4 versus 6.5 months in the EP and CEV arm, 
respectively, although without statistical significance (P=0.21). Overall 5-year 
survival was 3.5% in all patients, with 6% in LD-SCLC and 1% in ED-SCLC. During 
follow-up, several long-term survivors died of other causes than SCLC, giving a 5-
year disease-specific survival of 8.5% in the LD-SCLC group; 13% in EP-treated and 
4% in CEV-treated patients.  
 HRQOL analysis did not show any consistent difference between the two 
randomly assigned treatment groups, except for more nausea and vomiting in the EP-
chemotherapy group during the induction treatment period. Due to inferior 
compliance in completing questionnaires at baseline (66%), resulting in a low number 
of patients in the LD and ED groups, the HRQOL analyses were presented in the 
entire group only.  
 The results from this trial scientifically established cisplatin and etoposide as 
the routine primary chemotherapy regimen in LD-SCLC patients. In ED-patients, the 
survival data were equivalent in both treatment arms with no consistent differences in 
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HRQOL scales. Thus, anthracyclin-based chemotherapy is still, in addition to EP, an 
alternative in ED-SCLC disease.    
 
Paper II 
Second-line chemotherapy in recurrent small cell lung cancer. Results from a 
crossover schedule after primary treatment with cisplatin and etoposide (EP-regimen) 
or cyclophosphamide, epirubicin, and vincristin (CEV-regimen).  
 
This paper describes, in a non-randomised design, the follow-up of patients from the 
SCLC study with respect to recurrence and relapse-treatment. Detailed follow-up 
information were available in 382 (88%) of 436 patients. Of these, 286 patients (75%) 
developed relapse. Second-line chemotherapy was administered to 120 patients (42%) 
while the rest were treated with BSC without the use of chemotherapy. Among 
patients retreated with chemotherapy, 108 were treated with the opposite crossover 
regimen (52 with crossover CEV; 56 with crossover EP) and 12 retreated with the 
same induction regimen as they received in the primary situation. No survival 
difference was found between the two crossover groups with a median survival of 3.9 
and 4.5 months in the EP- and CEV-group, respectively (P=0.71). Due to quality 
assured follow-up data, a comparison between retreated patients versus patients 
receiving BSC was possible. This comparison showed a highly significant difference 
in favour of second-line chemotherapy with a median survival of 5.3 and 2.2 months 
in the retreated and the BSC group, respectively (P<0.0001). However, exploration of 
prognostic factors at baseline showed that the BSC group in general had a 
significantly worse prognosis when compared to the others. In patients administered 
crossover chemotherapy, possible prognostic factors for survival were investigated in 
univariate and multivariate models, revealing PS at relapse as the only independent 
prognostic factor of significance (P<0.001). 
To summarise, no differences between CEV- and EP-chemotherapy at relapse 
were seen, leaving both regimens optional for second-line chemotherapy. However, 
due to the non-randomised fashion of this comparative study, conclusions have to be 
interpreted with caution. Moreover, PS should be established in all relapsed SCLC 
patients, and used in the treatment decision-making process to evaluate the potential 
for meaningful treatment benefit.  
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Paper III 
Hypofractionated Palliative Radiotherapy (17 Gy per two fractions) in Advanced 
Non-Small-Cell Lung Carcinoma Is Comparable to Standard Fractionation for 
Symptom Control and Survival: A National Phase III Trial. 
 
This RCT compared different palliative radiotherapy schedules in locally advanced or 
metastatic NSCLC. Comparing one hypofractionated TRT schedule (17 Gy/2 
fractions, Arm A) versus two higher dose fractionated TRT schedules (42 Gy/15 
fractions, Arm B; 50 Gy/25 fractions, Arm C). 421 patients were included, of which 
395 participated in the HRQOL part of the study. The compliance rate of HRQOL 
questionnaires at baseline and throughout the follow-up time was very good (baseline 
97%, minimum 76%). No differences in palliative effect between the various TRT 
schedules were revaled, measured by patient completed questionnaires or by 
clinicians’ assessment. The beneficial effect on dyspnoea, cough and hemoptysis was 
equivalent across the treatment arms throughout the period of primary interest (up to 
week 22). Furthermore, no consistent differences in HRQOL outcomes until one year 
follow-up were seen. Finally, local symptomatic control within the radiotherapy fields 
was equal between the treatment arms, with about 40% being without significant 
tumour-related chest symptoms at the latest assessment time (P=0.64).  
Moreover, no difference in survival was observed with a median survival of 
8.2, 7.0, and 6.8 months in arm A, B, and C, respectively (P=0.83). Subgroup analysis 
in locally advanced disease (stage III) did not show any statistical significant 
difference in median survival (arm A, 9.2 months; arm B, 8.1 months; arm C, 7.5 
months) (P=0.47). However, a trend to more long-time survivors in the higher dose 
fractionated arms was found when good PS patients (Karnofsky score ≥ 80) were 
analysed, with a 3-year survival of 1%, 9%, and 6% in arm A, B, and C, respectively 
(P=0.06).  
Toxicity evaluated by the HRQOL questionnaires and clinicians’ assessment 
did not reveal any differences in side effects. Radiotherapy-induced oesophagitis 
appeared earlier in the short-course TRT-arm (Arm A) compared to the higher dose 
schedules (Arm B and C), but this was temporary and manageable.  
The patients included in this trial were highly homogenous related to other 
treatment interventions, as only six and seven patients received chemotherapy either 
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before or after TRT, respectively. This fact makes the HRQOL results interpretable 
according to the assigned treatment and follow-up period.  
The overall interpretation of this trial is that short-course palliative TRT with 
17 Gy in two fractions is safe to administrate and comparable with more protracted 
higher dose palliative TRT considering symptomatic effect, HRQOL and survival.  
  
Paper IV 
Immediate or delayed radiotherapy in advanced non-small cell lung cancer 
(NSCLC)? Data from a prospective randomised study.  
 
This paper is studying the same cohort of patients as in paper III. At baseline, the 
patients were stratified according to symptoms present (S-patients) or with none or 
minimal symptoms present (NS-patients). This separation gave the opportunity to 
explore the symptom development and HRQOL in two patient cohorts, differing with 
respect to disease-related symptoms, administered immediate TRT. 107 patients were 
categorised as NS-patients and 300 as S-patients. In general, NS patients had 
significantly better baseline characteristics concerning Karnofsky PS, weight loss, and 
stage distribution. These factors are all well known as significant prognosticators for 
survival in NSCLC and do explain the observed survival difference with median 
survival of 11.8 and 6.0 months in the NS- and S-group, respectively (P<0.0001). 
However, within each of the two stratified groups there were no differences in 
survival regarding the various TRT schedules.  
According to better baseline characteristics in NS-patients, the HRQOL 
baseline data were significantly better in most scales compared to S-patients. Whereas 
the HRQOL results were improved or stable in S-patients in the period of primary 
interest (up to week 22), there were a consistent deterioration and worsening in NS-
patients in the same period. From week 14, the HRQOL mean scores were 
overlapping (95% CI). Both groups developed a significant radiotherapy induced 
oesophagitis in the first weeks. 
Clinicians’ symptom assessments were consistent with the patient reported 
HRQOL data. As for HRQOL, S-patients had significantly more disease-related 
symptoms at baseline in all sacles except for emotional function, congnitive function 
and diarrhea, when compared to NS-patients. At follow-up, 14 weeks after completed 
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TRT, symptoms were equal in the two groups with exception of fatigue. At this point 
fatigue was still more frequent in the S-patient population.   
Since this study is a non-randomised comparison, the results should be 
interpreted with caution. However, longer term prevention of disease related 
symptoms and maintaining a reasonably good HRQOL in NS-patients given 
immediate TRT do not seem to occur. Furthermore, dysphagia and radiotherapy 
oesophagits were unnecessary induced in these otherwise symptom-free patients. Our 
data may indicate that patients with minimal or no tumour related chest symptoms do 
not benefit from immediate palliative TRT.  
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Discussion 
The basis for this thesis is two randomised national multicentre studies performed 
through NLCG. The Norwegian health care system provides an equal treatment policy 
independent of adress, social status and financial income. Furthermore, the quality 
assurance of cause of death is reliable through the national death registry. Since the 
community of lung cancer treating physicians in Norway is rather transparent, the 
loyalty to treatment guidelines and protocols is favourable. Thus, the percentage of 
potential patients enrolled in protocols is high, yielding a low selection bias. This 
renders high quality trial data, representative in the everyday clinic.    
 HRQOL assessments made by patients were one of the main goals in these 
studies. The SCLC study was initiated in the late 80s and the TRT study in 1993. The 
recognition of the importance of HRQOL assessments in palliative clinical trials has 
evolved during the 90s. The early studies by Kaasa et al. 131,132 during the mid 80s, 
pioneered evaluating quality-of-life aspects in lung cancer patients within clinical 
trials. These papers describe a self-developed questionnaire containing items on 
different disease- and treatment-related symptoms. The experience from this research 
was put into collaboration with the European Organisation for Research and 
Treatment of Cancer (EORTC). About 1990, the EORTC developed a core 
questionnaire for use in cancer patients (EORTC QLQ C-30) 101. Later, a lung cancer 
specific module to be used together with the core questionnaire was developed (QLQ 
LC-13) 103. The questionnaires were validated through international field studies and 
were found reliable and valid in lung cancer patients 133. These questionnaires 
(version 1) were therefore chosen as the main method for evaluating HRQOL in the 
studies described herein.    
 
SCLC, chemotherapy study 
The SCLC study represents the first large-scale oncology trial in Norway using 
HRQOL as one of the major end-points.   
The median survival difference of 7.8 to 10.2 months in favour of the EP-
regimen is highly statistically significant (P=0.0004). Important to notice is that the 
survival difference is not only a gain in median survival. The survival benefit is 
maintained throughout 5-years of follow-up.  
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This SCLC trial is the only published randomised trial strictly comparing EP- 
and CEV/CAV-chemotherapy. Two previous 3-armed RCTs have been performed, 
both with the third arm consisting of an alternating CAV/EP-regimen. The trial from 
Roth and colleagues 68 studying 437 ED-SCLC patients with CAV, EP, or alternating 
CAV/EP, did not find any survival difference across the arms, which is in accordance 
with the findings in our study. The study from the Japanese Group 69, including both 
LD- (N=146) and ED-patients (N=142), compared CAV (N=97), EP (N=97), and 
alternating CAV/EP (N=94). The investigators reported a significantly higher overall 
survival for LD patients receiving the alternating CAV/EP therapy (2-year survival of 
30%) when compared with CAV (15%) or EP (21%). However, no difference was 
observed between the EP- and the CAV-treatment group. In ED-patients, no 
difference between the treatment arms was seen. Our study is hitherto the largest 
study in LD-patients. The demonstrated survival benefit establishes the EP-regimen as 
the superior chemotherapy regimen and should be used routinely in LD-SCLC 
patients 134,135.  
 In our trial the thoracic radiotherapy was administered to LD-patients between 
course three and four to a total dose of 42 Gy in 15 fractions over three weeks. When 
this study was initiated, 42 Gy was considered an internationally acceptable 
fractionating scheme 136. Subsequent investigations have revealed that concomitant 
radiotherapy is more beneficial than sequential 83,137. Furthermore, accelerated 
radiotherapy may be even more effective if rapid clonogenic cells exist. The study by 
Turissi and co-workers 84 giving radiotherapy concurrent with EP-chemotherapy from 
day one, either normofractionated (1.8 Gy/25 fractions) or accelerated twice daily (1.5 
Gy twice daily/30 fractions), reported impressive 2- and 5-year survival rates. Median 
survival was 19 versus 23 months for those receiving once-daily therapy and twice-
daily therapy, respectively (P=0.04), with the corresponding 5-year survival rates of 
16% versus 26%. Our results are inferior compared to the Turissi study 84, but their 
promising results have not been been reproduced by others. Compared to other 
reports, however, our results in LD-disease are acceptable 135, but somewhat lower 
survival when compared with phase II and phase III reports from North America 138. 
The difference in outcome in LD-SCLC patients might be explained by less selection 
bias in our study compared to the US studies. Given the national SCLC incidence 
rates in Norway during the study period, close to 40% of all potential patients were 
actually included in this trial. In contrast, the Turissi study 84 was more selective 
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regarding the study population with patients primarily in PS 0-1, less weight loss and 
lower median age, when compared with our study population. Moreover, data from 
the US indicate that less than five percent of eligible patients in general are included 
in trials 139.  
Since there was no difference betwen the treatment arms with respect to ED-
patients in our study, an anthracyclin-based regimen seems an acceptable alternative 
to EP. However, two meta-analyses considering the role of cisplatin in SCLC found a 
significant survival improvement following cisplatin-based chemotherapy 71,72. 
Moreover, Chute et al. 140 reviewed 21 published phase III trials in North America 
with a total of 5746 ED-SCLC patients treated between 1972 and 1993. Trials from 
1972 through 1981 were mainly anthracyclin-based, while trials in the period 1982 to 
1990 were cisplatin-based. From the first to the second period, the authors found an 
increased survival from 7.0 to 8.9 months (P=0.001). These results are comparable 
with the findings in ED-patients in our trial where a survival of 6.5 and 8.4 months 
(P=0.21) in the CEV- and EP-arm were found, respectively. Keeping in mind the 
results of the meta-analysis, the superiority of EP chemotherapy in ED-SCLC is 
therefore likely to exist, but difficult to show in single trials with inadequate power.  
HRQOL assessment, defined as a secondary end-point, was considered 
essential in this trial, especially if the primary treatment outcomes turned out equal in 
the two treatment arms. Interpretation of HRQOL scores was, however, difficult due 
to a low baseline compliance (66%). Thereafter, the compliance rate was above 70% 
until week 38, but dropped to 62% at week 54. Due to logistic circumstances, 
HRQOL participation was restricted to 4 years of a total of 5.6 years accrual time. As 
a consequence, 72% of the patients were enrolled in this part of the study. Because of 
the low baseline compliance, the possibility of interpreting HRQOL data in subgroups 
became limited. Hence, HRQOL data are only presented in the entire group and not in 
the LD- and ED-subgroups. 
No substantial HRQOL differences between the two treatment groups were 
found, except for more emesis until week 14 in the EP group. Modern antiemitics 
with 5HT-3 antagonists were introduced in Norway around 1991, during this trial 
period. Exploration of HRQOL before or after this period revealed the same result 
with more emesis in the EP-arm. As the survival is equivalent in the ED-group, the 
chemotherapy regimen in ED-patients should be a matter of choice. However, based 
on the results of the meta-analysis 71,72 and the possibility of replacing cisplatin by 
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carboplatin, many clinicians today will choose carboplatin and etoposide as first 
choice in ED disease.  
Whereas 316 patients accepted to participate in the HRQOL evaluation, the 
compliance at baseline was 66% (N=209), while it was 89% (N=281) at week two. 
The reason for this low baseline compliance is obviously related to the physicians 
who either were not delivering or collecting the questionnaires at study entry. At the 
time when this study was running, research nurses or research assistants were not 
common in Norway. The high compliance from the mailed questionnaires, however, 
shows that most patients are positive to HRQOL-questionnaires. Studies with 
allocated research assistants and inclusion criteria requesting completed baseline 
HRQOL questionnaires prior to randomisation, is therefore recommended in order to 
improve HRQOL assessment in future studies 141.  
 
The crossover study (paper II) tested the alternative regimen at relapse. Former 
studies had shown that treatment with EP in previously anthracyclin-treated (CAV-
regimen) patients 142 was perhaps more effective than the reverse sequence 143. When 
the present study was designed (paper I), these two regimens were considered to be 
non-cross resistant 144,145. Thus, the alternative regimen was recommended at relapse. 
However, exploration of survival as the principal outcome did not reveal any 
difference between the crossover groups. No difference in survival in previously CEV 
treated patients retreated with EP, compared to the reverse setting, was exposed. 
There are many possible explanations for this lack of difference. Even though the 
baseline characteristics are similar in both groups, the two groups might be different 
biologically at the time of relapse. A significant difference in survival after first-line 
induction chemotherapy indicates that EP chemotherapy is more effective in SCLC. 
This disparity can lead to a non-reliable distinction in resistant and sensitive disease at 
relapse. Secondly, one could argue that the CEV- and EP-regimens are not equipotent. 
Finally, the sample size of the study population may be too small to detect any 
possibly existing difference. Therefore, having these considerations in mind, the 
interpretation of this study should be with caution. A more precise interpretation may 
be to regard the two crossover groups as two separate phase II studies with limited 
importance when compared to each other. 
Nevertheless, our results with a median survival of 5.3 months and a 1-year 
survival of 12 to 14% are comparable with findings from other second-line studies 
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using novel cytotoxic agents. No substantial increase in either median or 1-year 
survival is achieved when testing paclitaxel 146, gemcitabine 147, or topoisomerase I 
inhibitors like irinotecan 148 and topotecan 149. These phase II studies achieved a 
median survival of 5.0 to 7.1 months, and a limited 1-year survival of 10 to 20% with 
no long-time survivors. One phase III trial, comparing single drug topotecan versus 
the CAV-regimen, achieved survival rates comparable with our study 150. Thus, 
hitherto, no single standard salvage regimen has been recommended in the second-
line setting.  
Since valid follow-up data were accessible in most patients in the first-line 
protocol, we were able to compare patients receiving second-line treatment with those 
receiving BSC. Baseline characteristics of these two cohorts of patients revealed that 
patients selected to be retreated had significantly more favourable prognostic factors 
than the others. Therefore, the large difference in median survival between retreated 
patients and the BSC group may primarily reflect the prognostic features of the 
accrued patients and not the efficacy of the retreatment.  
Recently, a phase III trial comparing oral topotecan versus BSC in patients 
with recurrent SCLC, ineligible for further intravenously chemotherapy, has been 
published 151. Even though the study population was limited (N=141), a significantly 
improved median survival from 14 to 26 weeks (P=0.01) was achieved with less 
deterioration of HRQOL in favour of the topotecan treated patients. Although the 
evidence for benefit of second-line chemotherapy in recurrent SCLC is sparse, most 
clinicians will advocate chemotherapy if the patient’s PS is good. In our study, a 
prognostic factor analysis among the retreated patients revealed PS as a highly 
significant prognosticator for survival. Furthermore, the BSC patients had 
significantly worse PS at relapse compared to the actively treated patients. This 
emphasises the importance of PS as the main selection criteria for choosing which 
patients should receive second-line chemotherapy. Thus, if second-line treatment is 
considered, this should probably be restricted to PS 0-1 patients only. Consequently, 
estimating PS is mandatory and should be used actively in the clinical decision-
making process before giving second-line chemotherapy in relapsed SCLC patients.  
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NSCLC, palliative radiotherapy study 
The TRT study was initiated in 1993 with the principal aim to evaluate HRQOL and 
the treatment effect on symptoms in radiotherapy treated advanced NSCLC patients. 
Participation in the HRQOL part in this study was optional, however, 97% (395/407) 
of eligible patients volunteered to participate. Only ten baseline questionnaires were 
missing, giving an initial compliance of 97%. The compliance throughout the planned 
follow-up time was minimum 76% at week 38 and 81% at the latest assessment time 
at week 54. This high compliance rate makes the interpretations of the HRQOL data 
from this study highly valid and representative.  
All together, there were no differences in outcome of primary symptoms or 
HRQOL across the treatment arms, either in the period of primary interest or until 
week 54. Subgroup analyses according to NS- and S-patients were also performed, 
but still no differences were seen between the assigned treatment arms. The HRQOL 
results were supported by the clinicians’ assessment of the primary symptoms. With 
the equal survival in mind, these results support hypofractionated TRT with 17 Gy in 
two fractions in these patients.  
A Cochrane Collaboration review on palliative RT in advanced NSCLC 61 has 
evaluated ten RCTs (2001). Our study (unpublished summarised data) was one of 
these trials. Trials comparing RT with chemotherapy alone or in combination with RT 
were not included. After completion of this review, three other phase III trials have 
been published 152-154. These trials, addressing the question about fractionation, have 
used a large variety of schedules, ranging from 10 Gy in one fraction to 60 Gy in 30 
fractions. Table 10 gives an overview of these trials. 
The trials from the MRC in UK pioneered patient self-assessment as a major 
method for evaluating the effect on disease-related symptoms, in addition to 
clinicians’ assessment of primary symptoms. The first study (MRC I) 57 tested 
patients with a reasonably good PS by comparing hypofractionated or short-course 
TRT (8.5 Gy x 2) versus a traditional TRT fractionation schedule (3 Gy x 10). The 
second study (MRC II) 58 included patients with poor PS (PS 2-4) comparing a single 
fraction TRT (10 Gy x 1) versus the experimental arm in the MRC I study (8.5 Gy x 
2). Both studies used a diary card system, restricted to 6 months. There were no 
differences in palliation or survival across the arms. The inferior survival in MRC II 
compared to MRC I is explained by worse PS in the MRC II study. However, a 
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subgroup analysis of patients with stage III disease in the MRC I study, suggested that 
survival might be improved by protracted fractionation.  
 
Table 10. Different RCTs considering palliative TRT in advanced NSCLC 
    Symptom assessment  Median S  
 N Randomisation PS-status Patient Physician Outcome (months) Long-term S 
 
Simpson (1984) 
 
316 
4.0 Gy x 10 (split 2 wk) 
3.0 Gy x 10 
2.0 Gy x 20 
 
0-2 (3) 
 
no 
 
yes 
 
equal 
6.2  
6.4  
6.9 
 
3-year not reported
no difference 
 
Teo (1987) 
 
291 
 
2.5 Gy x 18 (45 Gy) 
7.8 Gy x 4 (31.2 Gy) 
 
0-2 (3) 
 
no 
 
yes 
better 
palliation in 
arm 45 Gy 
 
5.0 
5.0 
 
2-year 5%  
no difference 
MRC I (1991) 369 8.5 Gy x2 (17 Gy) 
3 Gy x 10 
0-2 (3) diary cards yes equal 5.9  
5.9  
2-year 5%  
no difference 
MRC II (1992) 235 8.5 Gy x 2 (17 Gy) 
10 Gy x 1 
2-4 diary cards yes equal 3.3  
4.0  
2-year 2-3% 
no difference 
Abratt (1995) 84 3.5 Gy x 10 (35 Gy) 
3.0 Gy x 15 (45 Gy) 
0-2 no yes equal 8.5  
8.5  
 
not reported 
MRC III (1996) 
Macbeth  
509 3.0 Gy 13 (39 Gy) 
8.5 Gy x 2 (17 Gy) 
0-2 questionnaires
diary cards 
yes equal 8.9  
7.1  
2-year 12% *  
2-year 9%  
Rees (1997) 216 8.5 Gy x 2 (17 Gy) 
4.5 Gy x 5 (22.5 Gy)  
0-3 questionnaires no equal 6.0  
6.0  
2-year not reported
no difference 
 
Reinfuss (1999) 
 
240 
4.0 Gy x 10 (split 4 wk) 
2.0 Gy x 25 
observation  (wait and see) 
 
1-3 
 
no 
 
no 
 
not reported 
9.0  
12.0  
6.0  
2-year  6% * 
2-year 18% * 
2-year 0%  
Nestle (2000) 152 2.0 Gy x 30 
2.0 Gy/twice/day x 8 (32 Gy)
0-3 diary cards yes equal 8.3  
8.4  
2-year 9% 
no difference 
 
Bezjak (2002) 
 
230 
 
4.0 Gy x 5 (20 Gy) 
10 Gy x 1 
 
0-3 
 
questionnaires
diary cards 
 
no 
better 
palliation in 
arm  20 Gy 
 
6.0 *  
4.2  
 
not reported 
 
Sundstrøm (2004) 
 
407 
8.5 Gy x 2 (17 Gy) 
2.8 Gy x 15 (42 Gy) 
2.0 Gy x 25 (50 Gy) 
 
0-3 
 
questionnaires
 
yes 
 
equal 
8.2  
7.0  
6.8  
3-year 1% 
3-year 6% 
3-year 6% 
 
Kramer (2005) 
 
297 
 
8.0 Gy x 2 (16 Gy) 
3.0 Gy x 10 
 
0-3(4)  
 
questionnaires
 
no 
longer 
palliation in  
arm 30 Gy 
 
not 
reported 
 
3-year 2% 
3-year 6% * 
Senkus-Konefka 
(2005) 
100 8.0 Gy x 2 (16 Gy) 
4.0 Gy x 5 
1-3(4) questionnaires yes equal 8.0 * 
5.3 
no difference 
S = survival 
* = p< 0.05 
 
Therefore, a third study (MRC III) 59 was implemented comparing higher dose 
(3 Gy x 13) versus short-course (8.5 Gy x 2) TRT in good PS patients with stage III 
tumours. The main end-point for this study was long-term survival. The trial was 
therefore extended to be the hitherto largest performed trial. To assess palliative 
benefit, questionnaires (Rotterdam Symptom Checklist 98) together with diary cards 
were used. The results showed that the palliative effect occurred more rapidly in the 
short-course arm, but the magnitude of palliation was equal. A small, but significant 
survival benefit was revealed in the higher dose TRT schedule, 2-year survival of 12 
versus 9% (P=0.03), respectively.  
 Five other trials (Simpson 155, Abratt 156, Rees 157, Nestle 158, and 
Senkus-Konefka 154), using various dose schedules, have not shown any difference in 
symptom palliation or long-term survival in favour of higher doses. However, three 
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trials have reported a difference in palliation 152,153,159, in which two also revealed a 
difference in median survival 152,153, in favour of higher dose schedules. The Canadian 
trial 152 compared a single fraction of 10 Gy versus 20 Gy in five fractions. A diary 
card method and questionnaires were used, but limited up to one month. Assessment 
of symptoms showed a greater improvement in several scales in favour of fractionated 
therapy. A significant difference in median survival with two months extended 
survival compared to the single fraction arm was exposed; however, this difference 
was restricted to good PS patients with stage III disease only. The recently published 
Dutch trial 153, comparing 8 Gy x 2 versus 30 Gy/10 fractions primarily in stage IV or 
poor PS stage III patients, revealed a better survival and longer duration of palliative 
response in the high dose arm. The older trial from Teo and colleagues 159 
investigated a higher dose normofractionated schedule (2.5 Gy x 18) versus a higher 
dose hypofractionated schedule (7.8 Gy x 4). The palliative effect, assessed by 
clinicians exclusively, was significantly better in the 45 Gy arm. No survival 
difference was exposed.  
The Canadian study 152 did show an inferior survival in good PS stage III 
patients given single fraction TRT. This was not shown in the MRC II 58 study, 
confined to low PS patients only. No other trials using a single fraction in one arm are 
published. A hypothesis of an existing dose-response relation between single fraction 
(10 Gy) versus 17 Gy/2 fractions or higher doses, can, however, explain the 
conflicting results from the Canadian trial 152.  
The results from the Dutch trial 153, mostly stage IV disease, showed improved 
survival in the high dose arm. These results are in contrast to all other trials including 
stage IV disease. However, the benefit was restricted to good PS patients. The Polish 
study 154, using the same hypofractionated schedule (8 Gy x 2), did, however, show a 
better median survival in the 16 Gy/2 fraction arm, which is in contrast to the Dutch 
results.  
Compared to the trials using diary cards and/or questionnaires for evaluating 
the palliative effect, our trial has the strength of high compliance rate and more 
extended evaluation (week 54). In our trial, no consistent long-term differences in 
HRQOL were seen beyond 6 months. Overall, there is no convincing evidence that 
higher dose TRT gives better palliation in the short- or the long-term perspective, and 
recommending a hypofractionated low dose schedule should be safe, at least in poor 
PS patients (PS ≥ 2). 
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However, some concern remains about TRT fractionation and long-term 
survival in localised stage III disease. There is a trend that some patients are long-
term survivors and might be cured with protracted higher dose TRT, even when the 
aim of the treatment is palliation. The MRC III 59 trial is the only trial performed with 
a sufficient power to detect a difference in long-term survival. The 3-arm trial in 
localised stage III disease from Reinfuss et al.160, comparing a split-course technique 
(4 Gy x 5 - split 4 weeks - 4 Gy x 5) versus a conventional fractionation schedule (2 
Gy x 25) versus wait and see (TRT when symptoms), supports this trend. No patients 
in the wait and see arm survived 2-years, compared to 18% and 6% in the fractionated 
and split-course schedule, respectively. While the statistical significant difference at 
2-years is based on a comparison between the two TRT arms combined versus wait 
and see, a survival comparison between the two TRT arms was not reported. The 
long-term survival data from our study show a trend (P=0.06) towards better survival 
in stage III good PS patients given the higher dose TRT (42 Gy/15 fractions, 50Gy/25 
fractions). Updated survival data reveal that the difference is maintained up to 5-
years. At this time, 5% is still alive in the protracted fractionated arms in contrast to 
none in the hypofractionated arm 161.  
 
Due to the large heterogeneity among these trials, the Cochrane Collaboration did not 
attempt performing any meta-analysis 61. The review concludes that the majority of 
patients should be treated with short-course radiotherapy since there is no strong 
evidence of greater palliation with more protracted TRT regimens. Moreover, there is 
evidence for a modest increase in survival in stage III patients with better PS given 
higher dose TRT. The use of higher dose palliative regimens should therefore be 
considered for selected patients with locally advanced disease and good PS. 
 
In paper IV, the HRQOL development in TRT treated patients without (NS-patients) 
versus those with symptoms (S-patients) at base-line is explored. This paper 
describes, in a non-randomised comparison, that the HRQOL is stable or improved in 
S-patients during the first 14 weeks in contrast to a negative development in NS-
patients. After week 14, there are no significant differences between the two groups 
based on mean scores with 95% CI. These findings suggest that administering TRT up 
front in patients without symptoms, yields no long-term benefits, but radiotherapy-
induced side-effects such as oesophagitis.     
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 For many years, there has been a controversy about the effect of immediate 
palliative TRT in asymptomatic stage III NSCLC patients 162-167. Studies addressing 
this topic are presented in Table 11. The study from Durrant and colleagues 162 
reported early in the 70s different treatment policies in locally advanced disease 
where a wait and see policy was one option. The radiotherapy given was 40 Gy in 13-
14 fractions compared to chemotherapy alone or TRT and chemotherapy combined. 
No differences were found regarding survival or in relation to a simplified HRQOL 
evaluation. The strength of this study is that it was a randomised trial. However, the 
TRT was given with cobalt-60 or orthovoltage therapy and may therefore be 
considered as suboptimal related to modern megavoltage radiotherapy.  
 
Table 11  Different trials evaluating benefit of immediate TRT in localised 
asymptomatic NSCLC 
  
N 
 
Treatment 
N 
treatment arms
 
Design 
Palliative 
outcome 
Median S 
(months) 
 
Durrant (1971) 
 
249 
Wait and see 
Immediate TRT 
Chemotherapy 
Combined 
63 
62 
63 
61 
 
randomised
 
equal 
8.4  
8.3  
8.7 
8.8 
Carroll (1986) 134 Wait and see 
Immediate TRT 
48 
86 
non-
randomised
not assessed not 
reported 
Falk (2002) 
MRC 
230 Wait and see 
Immediate TRT 
115 
115 
randomised equal 7.9  
8.3  
Sundstrøm (2005) 407 Immediate TRT non-symptomatic 
Immediate TRT symptomatic 
107 
300 
non-
randomised
inferior 
stable/improved 
11.8  
6.0  
 S= survival 
 
Carroll and co-workers 167 published a comparison between immediate TRT or 
watchful waiting until treatment was required due to symptoms. In each case, 
thorough information about the different treatment strategies was presented to the 
patients at diagnosis. A watch policy was chosen in patients accepting a wait and see 
strategy. Of these, 46% were estimated not to require any TRT in the follow-up 
period. However, neither HRQOL nor survival data were presented.  
In 2002, Falk and colleagues 168 published a randomised trial of immediate or 
delayed TRT in patients judged with minimal or no tumour related chest symptoms at 
diagnosis. This MRC trial 168 performed a thorough evaluation of HRQOL and 
symptoms using the same methods as in previous MRC trials 57-59. The majority of 
patients were treated with either 17 Gy in two fractions or a single fraction (10 Gy). 
No significant differences were found in survival, or in activity level, anxiety, 
depression, and psychological distress as recorded by the patients. In the delayed 
group, 42% received TRT during follow-up. Only two patients were treated with 
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chemotherapy. It was concluded that immediate TRT, when compared to TRT 
delayed until symptoms, yielded no improvement of symptom control, HRQOL, or 
survival.  
The patients accrued in this MRC trial 168 as well as the NS patients in our 
present trial, were categorised with minimal or none disease-related chest symptoms 
at diagnosis. However, baseline characteristics were different as our NS-patients had 
more favourable PS and less chest symptoms when compared to the MRC patients. In 
fact, a large proportion of the patients in the MRC study did have some symptoms at 
baseline, and may not be comparable with our NS-patients. The observed difference 
in median survival (NS patients 11.8 months, MRC immediate 8.3 months, MRC 
delayed 7.9 months) may be explained by this discrepancy.  
Since the late 90s, palliative chemotherapy has been considered standard 
treatment in advanced NSCLC 25. Thus, a repeated confirmatory TRT trial in this 
setting is therefore not ethically or possible to perform. Anyway, since our patients 
were treated with TRT only, our trial is comparable with the Falk study 168. No other 
confounding treatment modalities were used. The decreasing HRQOL observed in our 
NS patients after the TRT administration, strongly supports the conclusion from the 
MRC trial. Thus, a wait-and-see policy, i.e. delaying palliative TRT in advanced 
NSCLC patients until symptomatically needed, appears to be safe and acceptable.
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Conclusions and clinical significance of 
the studies 
The results from this thesis can be summarised as follows: 
 
• Chemotherapy with the EP-regimen is superior to CEV in small cell lung cancer. 
A highly significant difference in LD-SCLC shows that EP should be standard 
regimen in this subgroup of patients. The lack of survival difference between the 
treatment arms in ED-SCLC leaves anthracyclin-based chemotherapy 
(CEV/CAV-regimen) an alternative to EP in this patient subgroup.  
 
• Second-line chemotherapy in recurrent SCLC disease is associated with poor 
prognosis. No difference in treatment effect in either crossover treatment (EP 
versus CEV) was found, making the choice optional for which second-line 
regimen to be used. PS is an independent prognostic factor in recurrent SCLC and 
should be used as the principal selection marker in the treatment decision for or 
against second-line chemotherapy.  
 
• Hypofractionated palliative TRT (17 Gy in two fractions) in advanced NSCLC is 
comparable with more protracted higher dose TRT with respect to HRQOL, 
disease related symptom relief and survival. In most NSCLC patients where 
palliative TRT are needed, this fractionation schedule should be used. Selected 
stage III patients with favourable PS should be treated with a protracted 
fractionated higher dose TRT schedule. 
 
• Advanced NSCLC patients with disease-related chest symptoms at diagnosis will 
benefit from palliative TRT. Patients without or with minimal symptoms do not 
benefit from immediate TRT. On the contrary, they experience a reduced HRQOL 
due to therapy-induced side effects. A wait and see policy considering palliative 
TRT is recommended until the patient develops symptoms.   
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Strategy for further clinical research - 
within the context of the Norwegian Lung 
Cancer Study Group 
This thesis is based on multicentre studies from the collaborative work by the 
Norwegian Lung Cancer Study Group. The collaboration is focused around clinical 
research in lung cancer patients. The strength of the group is the multiprofessionality 
of clinicians participating, a common agreement on protocols and issues to be 
investigated, a high loyalty and compliance into protocols, and an organisation with 
alternating sites to be responsible for research protocols. This makes it possible to 
carry out national trials ensuring low selection bias in the study populations.  
Most of our trials focus HRQOL evaluation as a central end-point. One main 
lesson from the trials addressed in this thesis is that compliance of baseline 
questionnaires is critical. After the first study presented herein, completed baseline 
HRQOL questionnaires became a crucial inclusion criterion.  
The collaborative work of the group has expanded through the 90s and in the 
middle of this decade with several trials completed, ongoing or forthcoming. The 
group will continue its main focus on clinical trials (phase II and phase III), increase 
the quality of lung cancer detection, staging, treatment, and follow-up through 
published “National Guidelines”. Further, our collaborative group will also act as a 
national reference group for advice on treatment recommendations.
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